{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-040826","form_type":"8-K","ticker":"ADPT","cik":"0001478320","company_name":"Adaptive Biotechnologies Corp","filed_at":"2021-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.221701+00:00","generated_at":"2026-06-29T22:31:19.784175+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Adaptive Biotechnologies Q2 revenue $38.5M, +83% YoY; raises FY2021 guidance to $148M-$155M","bullets":["Revenue $38.5M (+83% YoY); sequencing revenue $18.6M (+132%), development revenue $20.0M (+53%).","Net loss $49.3M vs $33.5M YoY; adjusted EBITDA loss $35.6M vs $28.5M.","FY2021 revenue guidance raised to $148M-$155M (prior $145M-$155M).","clonoSEQ volume +75% YoY; signed agreements with Vaccibody and Moderna for T-cell data and COVID vaccine T-cell response measurement.","Cash and marketable securities $689.5M as of June 30, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-040826","json":"https://secwatch.observer/filing/0001564590-21-040826.json","markdown":"https://secwatch.observer/filing/0001564590-21-040826.md","text":"https://secwatch.observer/filing/0001564590-21-040826.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1478320/000156459021040826/0001564590-21-040826-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1478320/000156459021040826/adpt-8k_20210804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T22:31:19.784175+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}